gutflix
GI learning, personalised

Summary

TWELVE-MONTH OUTCOMES OF TREATMENT WITH USTEKINUMAB IN PATIENTS WITH CROHN'S DISEASE, IN A REAL-LIFE SETTING IN GREECE: INTERIM ANALYSIS OF THE 'REASSURE' STUDY

Spyridon Michopoulos

UEG Week Copenhagen 2023 | Poster

IBD

October 15, 2023

The REASSURE study reports 84% 12-month ustekinumab persistence in 169 Greek Crohn's disease patients, with significant improvements in disease activity, quality of life, and work productivity measures.

KEY POINTS

- At 12 months, 84.0% of patients remained on ustekinumab therapy; 14.2% discontinued, primarily due to lack or loss of efficacy (10/24 discontinuations) or safety issues (8/24).
- Disease activity measured by Harvey-Bradshaw Index improved significantly from baseline median 8.0 with a median change of -4.0 at 12 months, and 77.9% of patients remaining on treatment had no disease activity (HBI 0-4 points).
- Quality of life (IBDQ) and fatigue (FACIT-F) scores improved significantly at 12 months, with IBDQ response (≥16 point improvement) in 51.6% and FACIT-F significant improvement (≥4 points) in 50.8% of patients with available data.
- Work productivity loss decreased significantly with a median change of -10.0 at 12 months; 56.1% of employed patients achieved clinically meaningful improvement (≥7% decrease).
- Ustekinumab-related adverse events occurred in 18.3% and serious adverse events in 4.7% of patients; one death occurred unrelated to ustekinumab.
- This real-world Greek study enrolled patients from April 2019 to March 2022 across 19 gastroenterology clinics; 35.5% were biologic-naïve and outcomes were similar across treatment lines.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/bb6dfae6-743b-11ee-aa7e-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.